Recro Pharma, Inc. (NASDAQ:REPH) has been given a $11.00 price objective by stock analysts at Piper Jaffray Companies in a research note issued on Tuesday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ target price suggests a potential upside of 40.31% from the company’s current price.

Several other equities research analysts have also recently issued reports on the stock. Janney Montgomery Scott cut shares of Recro Pharma from a “buy” rating to a “fair value” rating and cut their price objective for the stock from $21.00 to $6.50 in a research report on Wednesday, June 14th. Aegis restated a “buy” rating and set a $11.00 price objective on shares of Recro Pharma in a research report on Monday, March 27th. Zacks Investment Research upgraded shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a research report on Wednesday, May 17th. Finally, Roth Capital set a $20.00 price objective on shares of Recro Pharma and gave the stock a “buy” rating in a research report on Saturday, May 13th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Recro Pharma presently has a consensus rating of “Buy” and a consensus target price of $14.00.

Shares of Recro Pharma (NASDAQ:REPH) remained flat at $7.84 during mid-day trading on Tuesday. 50,849 shares of the company’s stock traded hands. Recro Pharma has a 12 month low of $5.81 and a 12 month high of $10.85. The firm’s market capitalization is $149.35 million. The company’s 50 day moving average price is $7.08 and its 200 day moving average price is $7.64.

Recro Pharma (NASDAQ:REPH) last issued its earnings results on Thursday, May 11th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.15. Recro Pharma had a negative net margin of 45.15% and a negative return on equity of 61.09%. The business had revenue of $18.74 million during the quarter, compared to analysts’ expectations of $15.58 million. Equities research analysts expect that Recro Pharma will post ($2.35) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Piper Jaffray Companies Analysts Give Recro Pharma, Inc. (REPH) a $11.00 Price Target” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/07/26/piper-jaffray-companies-analysts-give-recro-pharma-inc-reph-a-11-00-price-target.html.

In other Recro Pharma news, major shareholder Stonepine Capital Management, sold 510,000 shares of Recro Pharma stock in a transaction dated Friday, May 12th. The shares were sold at an average price of $7.40, for a total transaction of $3,774,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider James E. Flynn sold 62,868 shares of Recro Pharma stock in a transaction dated Thursday, June 8th. The shares were sold at an average price of $7.06, for a total transaction of $443,848.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,187,699 shares of company stock valued at $8,749,514. Company insiders own 21.60% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. KCG Holdings Inc. acquired a new position in Recro Pharma during the first quarter valued at approximately $173,000. Renaissance Technologies LLC raised its position in Recro Pharma by 245.1% in the first quarter. Renaissance Technologies LLC now owns 63,500 shares of the specialty pharmaceutical company’s stock valued at $555,000 after buying an additional 45,100 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in Recro Pharma during the first quarter valued at approximately $1,601,000. MARSHALL WACE ASIA Ltd acquired a new position in Recro Pharma during the first quarter valued at approximately $1,601,000. Finally, Segantii Capital Management Ltd raised its position in Recro Pharma by 602.1% in the first quarter. Segantii Capital Management Ltd now owns 26,678 shares of the specialty pharmaceutical company’s stock valued at $233,000 after buying an additional 22,878 shares during the last quarter. Institutional investors and hedge funds own 64.20% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.